Patents Assigned to Universite de Montpellier 1
  • Glycoclusters and their pharmaceutical use as antibacterials
    Patent number: 10105380
    Abstract: A molecule responding to formula (I) of the glycocluster type with galactose residues at their extremities. Simple and efficient methods for the preparation of these compounds. Medical use of compounds (I) as inhibitors of infections by Pseudomonas aeruginosa, more specifically as inhibitors of Pseudomonas aeruginosa's virulence.
    Type: Grant
    Filed: September 22, 2014
    Date of Patent: October 23, 2018
    Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE DE MONTPELLIER 1
    Inventors: Francois Morvan, Jean-Jacques Vasseur, Caroline Ligeour, Yann Chevolot, Eliane Souteyrand, Olivier Vidal, Alice Goudot, Sebastien Vidal
  • Methods for selecting competent oocytes and competent embryos with high potential for pregnancy outcome
    Patent number: 10059994
    Abstract: The present invention relates to a method for selecting a competent oocyte or a competent embryo by determining the expression level of specific microRNA species in a body fluid or in cumulus cells.
    Type: Grant
    Filed: November 21, 2016
    Date of Patent: August 28, 2018
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), UNIVERSITE DE MONTPELLIER 1, CENTRE HOSPITALIER UNIVERSITAIRE DE MONTPELLIER
    Inventors: Samir Hamamah, Said Assou
  • Flavonoid derivative compounds and method for preparing same by depolymerization of condensed tannins
    Patent number: 10030009
    Abstract: A compound of general formula (I) in which R1, R2, R3 and R5, identical or different, each represent a hydrogen atom or a hydroxyl group, optionally protected by a protecting group. R4 represents a hydrogen atom or an —OR7 group, in which R7 represents a hydrogen atom, a protecting group or a gallate group. R6 represents a hydroxyl group, optionally protected by a protecting group. R?1, R?2, R?3 and R?4, identical or different, each represent a hydrogen atom or a substituent not comprising a mesomeric electron withdrawing group conjugated with the furan ring. A substituent from R?1, R?2, R?3 and R?4 representing the covalent bond with the pyran ring or one of the salts of same. A method for obtaining such a compound includes a step of depolymerization of condensed tannins in the presence of an acid by means of a nucleophile derived from furan.
    Type: Grant
    Filed: August 3, 2015
    Date of Patent: July 24, 2018
    Assignees: INSTITUT NATIONAL DE LA RECHERCHE AGRONOMIQUE, CENTRE INTERNATIONAL D'ETUDES SUPERIEURES EN SCIENCES AGRONOMIQUES, UNIVERSITE DE MONTPELLIER 1
    Inventors: Laurent Roumeas, Hélène Fulcrand, Chahinez Aouf, Eric Dubreucq
  • Inhibitors of apoptosis and uses thereof
    Patent number: 9814758
    Abstract: The invention relates to fragments of the Death-Domain Associated protein (DAXX protein) and of the Fas-Associated Death Domain protein (FADD protein) that inhibit cell apoptosis, in particular cell apoptosis mediated by the Fas receptor. The invention also relates to derivatives of said anti-apoptotic fragments, conjugates comprising said fragments, pharmaceutical compositions comprising said fragments, and to the medical applications of said fragments, derivatives, conjugates, and pharmaceutical compositions thereof in the treatment or prevention of diseases and conditions associated with apoptosis.
    Type: Grant
    Filed: November 17, 2011
    Date of Patent: November 14, 2017
    Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE-CNRS, UNIVERSITE MONTPELLIER 2-SCIENCES ET TECHNIQUE, UNIVERSITE DE MONTPELLIER 1
    Inventors: Stéphanie Barrere, Joël Nargeot, Bernard Lebleu, Prisca Boisguerin, Christophe Piot
  • 5?-nucleotidase inhibitors and therapeutic uses thereof
    Patent number: 9783541
    Abstract: The subject matter of the present invention is compounds which have a 6-aminopurine backbone corresponding to formula (I): in which R1, R2, R3, X, Y and Z are as defined in any one of claims 1 to 5, and Ar is a biphenyl or a naphthyl which may be substituted with R3, for use in the treatment of cancer.
    Type: Grant
    Filed: September 29, 2014
    Date of Patent: October 10, 2017
    Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE-CNRS, HOSPICES CIVILS DE LYON, ECOLE NORMALE SUPERIEURE DE LYON, UNIVERSITE CLAUDE BERNARD LYON 1, UNIVERSITE DE MONTPELLIER 1
    Inventors: Laurent Chaloin, Suzanne Peyrottes, Corinne Lionne, Zsuzsanna Marton, David Egron, Remi Guillon, Christian Perigaud, Charles Dumontet, Lars Petter Jordheim, Isabelle Krimm
  • Association of poly(N-acryloylglycinamide) with at least one active principle
    Patent number: 9687552
    Abstract: The present invention relates to an association of poly (N-acryloyl glycinamide) with at least one active principle and/or at least one product which is visible in medical imaging, in a physiologically acceptable aqueous medium.
    Type: Grant
    Filed: February 26, 2013
    Date of Patent: June 27, 2017
    Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT REGIONAL DU CANCER DE MONTPELLIER, UNIVERSITE DE MONTPELLIER 1
    Inventors: Mahfoud Boustta, Pierre-Emmanuel Colombo, Michel Vert
  • METHODS FOR SELECTING COMPETENT OOCYTES AND COMPETENT EMBRYOS WITH HIGH POTENTIAL FOR PREGNANCY OUTCOME
    Publication number: 20170067105
    Abstract: The present invention relates to a method for selecting a competent oocyte or a competent embryo by determining the expression level of specific microRNA species in a body fluid or in cumulus cells.
    Type: Application
    Filed: November 21, 2016
    Publication date: March 9, 2017
    Applicants: INSERM (Institut National de la Sante et de la Recherche Medicale), UNIVERSITE DE MONTPELLIER 1, Centre Hospitalier Universitaire de Montpellier
    Inventors: Samir HAMAMAH, Said ASSOU
  • Methods for determining developmental stage of human cumulus cells
    Patent number: 9481863
    Abstract: The present invention relates generally to the fields of reproductive medicine. More specifically, the present invention relates to a method determining the developmental stage of human cumulus cells issues from MII oocyte.
    Type: Grant
    Filed: June 29, 2012
    Date of Patent: November 1, 2016
    Assignees: INSERM (Institut National de la Santé et de la Recherche Médicale), CENTRE HOSPITALIER UNIVERSITAIRE DE MONTPELLIER, UNIVERSITE DE MONTPELLIER 1
    Inventor: Samir Hamamah
  • Methods for assessing endometrial receptivity of a patient after controlled ovarian hyperstimulation
    Patent number: 9453259
    Abstract: Disclosed herein are methods and kits for assessing the endometrial receptivity of a patient after controlled ovarian hyperstimulation. More particularly, provided herein is a method for assessing the endometrial receptivity of a patient after controlled ovarian hyperstimulation, comprising a step consisting of measuring the expression level of at least one gene selected from fifteen genes in an endometrial biopsy sample obtained from the patient wherein the genes are FGFBP1, MUC20, TMPRSS3, PRUNE2, HES2, MGST1, ERRFI1, EDN1, SLC17A7, MET, CPT1B, DCDC2, LRRC39, IL18RAP, and FOXP1.
    Type: Grant
    Filed: October 22, 2012
    Date of Patent: September 27, 2016
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE DE MONTPELLIER 1, Centre Hospitalier Universitaire de Montpellier
    Inventors: Samir Hamamah, Delphine Haouzi
  • Anti-Axl antibodies and uses thereof
    Patent number: 9409988
    Abstract: The present invention relates to anti-Axl antibodies and uses thereof in diagnostic and therapeutic methods. More particularly, the present invention relates to a monoclonal antibody having specificity for Axl comprising an heavy chain variable region comprising SEQ ID NO:2 in the H-CDR1 region, SEQ ID NO:3 in the H-CDR2 region and SEQ ID NO:4 in the H-CDR3 region; and a light chain variable region comprising SEQ ID NO: 6 in the L-CDR1 region, SEQ ID NO:7 in the L-CDR2 region and SEQ ID NO:8 in the L-CDR3 region. Said monoclonal antibody binds to the extracellular domain of Axl via, SEQ ID NO:9 and SEQ ID NO: 10.
    Type: Grant
    Filed: June 22, 2012
    Date of Patent: August 9, 2016
    Assignees: INSERM (Institut National De La Sante Et De La Recherche Medicale), ORIBASE Pharma, UNIVERSITE De Montpellier 1, INSTITUT Regional Du Cancer De Montpellier-Val D'Aurelle
    Inventors: Bruno Robert, Benedicte Fauvel, Gwenael Cheve, Aziz Yasri, Christel Larbouret, Wilhem Leconet, Thierry Chardes, Christian Larroque, Andre Pelegrin
  • METHODS FOR SELECTING COMPETENT OOCYTES AND COMPETENT EMBRYOS WITH HIGH POTENTIAL FOR PREGNANCY OUTCOME
    Publication number: 20160201128
    Abstract: The present invention relates to a method for selecting a competent oocyte or a competent embryo.
    Type: Application
    Filed: July 24, 2015
    Publication date: July 14, 2016
    Applicants: INSERM (Institut National de la Sante et de la Recherche Medicale), UNIVERSITE DE MONTPELLIER 1, Centre Hospitalier Universitaire de Montpellier
    Inventors: Samir HAMAMAH, Said ASSOU
  • Hydrophobic polymer for producing medical devices visible in MRI
    Patent number: 9358324
    Abstract: The present invention relates to a hydrophobic polymer used in particular to produce and/or coat medical devices, in particular implantable medical devices, that are visible in magnetic resonance imaging, characterized in that it comprises at least one monomer unit on which is grafted a chelating ligand of a paramagnetic ion complexed with such a paramagnetic ion, said monomer unit having at least one carbonyl group, said monomer unit comprising, prior to grafting, at least one hydrogen atom in the ? position of said at least one carbonyl group, and said grafting of the chelating ligand taking place in the area of said at least one hydrogen atom in the ? position of said at least one carbonyl group.
    Type: Grant
    Filed: July 7, 2010
    Date of Patent: June 7, 2016
    Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE DE MONTPELLIER 2, UNIVERSITE DE MONTPELLIER 1, CENTRE HOSPITALIER UNIVERSITAIRE DE NIMES
    Inventors: Sebastien Blanquer, Jean Coudane, Renaud De Tayrac, Xavier Garric, Vincent Letouzey, Olivier Guillaume
  • Anti-Axl antibodies and uses thereof
    Patent number: 9249228
    Abstract: The present invention relates to anti-Axl antibodies and uses thereof in diagnostic and therapeutic methods. More particularly, the present invention relates to a monoclonal antibody having specificity for Axl comprising an heavy chain variable region comprising SEQ ID NO:2 in the H-CDR1 region, SEQ ID NO:3 in the H-CDR2 region and SEQ ID NO:4 in the H-CDR3 region; and a light chain variable region comprising SEQ ID NO: 6 in the L-CDR1 region, SEQ ID NO:7 in the L-CDR2 region and SEQ ID NO:8 in the L-CDR3 region. Said monoclonal antibody binds to the extracellular domain of Axl via, SEQ ID NO:9, SEQ ID NO: 10 and SEQ ID NO: 11.
    Type: Grant
    Filed: June 22, 2012
    Date of Patent: February 2, 2016
    Assignees: ORIBASE PHARMA, Institut Regional du Cancer de Montpellier-Val d' Aurelle, INSERM (Institut National de la Sante et de la Recherche Medicale), UNIVERSITE DE MONTPELLIER 1
    Inventors: Bruno Robert, Benedicte Fauvel, Gwenael Cheve, Aziz Yasri, Christel Larbouret, Wilhem Leconet, Thierry Chardes, Christian Larroque, Andre Pelegrin
  • FLT3 RECEPTOR ANTAGONISTS FOR THE TREATMENT OR THE PREVENTION OF PAIN DISORDERS
    Publication number: 20150307887
    Abstract: The present invention relates to FLT3 receptor antagonists or inhibitors of FLT3 receptor gene expression for the treatment or the prevention of pain disorders.
    Type: Application
    Filed: July 8, 2015
    Publication date: October 29, 2015
    Applicants: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITE DE MONTPELLIER 1, UNIVERSITE MONTPELLIER 2 SCEINCES ET TECHNIQUES
    Inventor: Jean VALMIER
  • Anti-human HER3 antibodies and uses thereof
    Patent number: 9127065
    Abstract: The present invention provides for isolated anti-human-HER3 antibodies or fragments thereof. More particularly the present invention provides an isolated monoclonal antibody that specifically binds to the extracellular domain of HER-3 and competes for binding to the extracellular domain of human HER-3 with the antibody produced obtainable from hybridoma deposited as CNCM-I-4486. The antibodies described in the present invention are useful for the treatment of cancer.
    Type: Grant
    Filed: May 21, 2012
    Date of Patent: September 8, 2015
    Assignees: Institut National de la Sante et de la Recherche Medicale (INSERM), Centre Val d'Aurelle—Paul Lamarque, Universite de Montpellier 1
    Inventors: Thierry Chardes, Andre Pelegrin, Christel Larbouret, Nadege Gaborit, Yassamine Lazrek
  • Methods for selecting competent oocytes and competent embryos with high potential for pregnancy outcome
    Patent number: 9121066
    Abstract: The present invention relates to a method for selecting a competent oocyte or a competent embryo by determining the expression level of specific microRNA species in a body fluid or in cumulus cells.
    Type: Grant
    Filed: November 24, 2011
    Date of Patent: September 1, 2015
    Assignees: Institut National de la Sante et de la Recherche Medicale (INSERM), Universite de Montpellier 1, Centre Hospitalier Universitaire de Montpellier
    Inventors: Samir Hamamah, Said Assou
  • FLT3 receptor antagonists for the treatment or the prevention of pain disorders
    Patent number: 9109227
    Abstract: The present invention relates to FLT3 receptor antagonists or inhibitors of FLT3 receptor gene expression for the treatment or the prevention of pain disorders.
    Type: Grant
    Filed: January 5, 2011
    Date of Patent: August 18, 2015
    Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITE DE MONTPELLIER 1, UNIVERSITE MONTPELLIER 2 SCIENCES ET TECHNIQUES
    Inventor: Jean Valmier
  • Methods for selecting competent oocytes and competent embryos with high potential for pregnancy outcome
    Patent number: 9090938
    Abstract: The present invention relates to a method for selecting a competent oocyte or a competent embryo.
    Type: Grant
    Filed: February 20, 2015
    Date of Patent: July 28, 2015
    Assignees: Institut National de la Sante et de la Recherche Medicale (INSERM), Universite de Montpellier 1, Centre Hospaitalier Univeritaire de Montpelier
    Inventors: Samir Hamamah, Said Assou, John De Vos
  • Use of constrained peptide mimic oligomers as vectorization agents
    Patent number: 9061069
    Abstract: The invention relates to the use of oligomers having constrained dipeptide or tripeptide motifs as agents for the vectorization of active ingredients.
    Type: Grant
    Filed: August 2, 2010
    Date of Patent: June 23, 2015
    Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE DE MONTPELLIER 1, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
    Inventors: Muriel Amblard, Jean Martinez, Lubomir Vezenkov, Jean-Francois Hernandez, Marcel Garcia, Marie Maynadier
  • METHODS FOR SELECTING COMPETENT OOCYTES AND COMPETENT EMBRYOS WITH HIGH POTENTIAL FOR PREGNANCY OUTCOME
    Publication number: 20150167079
    Abstract: The present invention relates to a method for selecting a competent oocyte or a competent embryo.
    Type: Application
    Filed: February 20, 2015
    Publication date: June 18, 2015
    Applicants: Institut National de la Sante et de la Recherche Medicale (INSERM), Universite de Montpellier 1, Cetre Hospitalier Universitaire de Montpellier
    Inventors: Samir HAMAMAH, Said ASSOU, John DE VOS